Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis: Recent Updates : Episode 1
Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis - Recent Updates
In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.
2:09 Early intervention with high-efficacy DMTs in MS
4:26 Anti-CD20 antibodies in MS
8:26 B-cell therapies in MS
10:17 Choosing among different anti-CD20 therapies
13:50 Ublituximab and ULTIMATE I, II trials
22:22 Ublituximab in treatment naïve patients
23:16 Ublituximab in patients with highly active MS
25:45 Bridging the gap between immunology and clinical presentation of MS
28:43 Epstein Barr virus (EBV) and MS
44:46 Addressing patient concerns about EBV and MS
Related Videos
Related Content
